appScorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Strides Pharma Science Ltd
STAR
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key MetricsEdit
Forecast & RatingsDetailed Forecast
Analysts have suggested that investors can buy this stock
Company Profile
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
PeersCompare with peers
Sun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Financial TrendFinancial statements
Holdings TrendDetailed holdings
High Pledged Promoter HoldingLower pledged promoter holdings is considered better
A significant proportion of promoter holdings is pledged
Mutual Fund HoldingIncreasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock
In last 3 months, mutual fund holding of the company has almost stayed constant
Recent NewsAll news
Strides Pharma gains on transfer of Bengaluru facility to Syngene
3 hours ago•Moneycontrol
Strides Pharma rallies after seizure drug receives US FDA approval
1 week ago•Moneycontrol
Strides Pharma Standalone September 2023 Net Sales at Rs 540.29 crore, up 12.27% Y-o-Y
1 month ago•Moneycontrol
Recent EventsAll events
Press Release
Strides Pharma Science Limited has informed the Exchange regarding a press release dated December 01, 2023, titled "Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal". | Download
Strides Pharma Science Limited has informed the Exchange regarding a press release dated December 01, 2023, titled "Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal". | Download
Press Release
Strides Pharma Science Limited has informed the Exchange regarding a press release dated November 23, 2023, titled "Strides receives USFDA approval for Generic Suprepￂﾮ Bowel Prep Kit". | Download
Strides Pharma Science Limited has informed the Exchange regarding a press release dated November 23, 2023, titled "Strides receives USFDA approval for Generic Suprepￂﾮ Bowel Prep Kit". | Download
Cash Dividend
Final • Div/Share: ₹ 1.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant